microdosing glp-1 research People Are Weight-Loss Drugs Such as Ozempic and Wegovy. Here's Why Interview with Dr. Tyna Moore,

Within the black box, the FDA explains that the medications cause rodents to develop thyroid C-cell tumors, but that it is unknown whether the same occurs in humans

Kosiborod M, Lam CSP, Kohsaka S, et al

Wang, Q., Wang, D., Cheng, A., Sun, F

At Lite Medical, we use advanced therapiesincluding low-dose GLP-1s and peptidesto target the root cause of your discomfort

In a large Phase 2 clinical trial involving adults with obesity: Participants experienced up to 17.5% average weight reduction at 24 weeks Weight loss reached approximately 24.2% at 48 weeks at higher doses (Lilly Investor Relations) Subsequent late-stage studies have suggested even greater reductions over longer periods, reinforcing the potential of triple-agonist therapies in metabolic medicine